pharma · Myelofibrosis · Acute Myeloid Leukemia
Karyopharm Therapeutics
Karyopharm Therapeutics Inc
Karyopharm Therapeutics clinical programs — 24 development programs from ClinicalTrials.gov with phase, modality, indication, and trial identifiers.
Company details
- Status
- Public
- HQ
- 85 Wells Avenue, Newton, MA 02459, US
- Employees
- 313
- Programs
- 82
- Drugs
- 53
- Patents
- 38
Karyopharm Therapeutics projects
24 ClinicalTrials.gov programs sponsored by Karyopharm Therapeutics.
Karyopharm Therapeutics has 24 clinical development programs indexed from ClinicalTrials.gov, including phase, modality, indication text, and linked NCT identifiers.
Clinical programs
-
Eltanexor
Karyopharm Therapeutics Inc
Relapsed Myelodysplastic Syndrome
1 trial -
KCP-330
Karyopharm Therapeutics Inc
Sarcoma
1 trial -
KPT-330
Karyopharm Therapeutics Inc
Solid Tumors
1 trial -
KPT-330
Karyopharm Therapeutics Inc
Diffuse Large B-Cell Lymphoma
1 trial -
KPT-330
Karyopharm Therapeutics Inc
Hematological Malignancies
1 trial -
KPT-330
Karyopharm Therapeutics Inc
Relapsed Acute Lymphoblastic Leukemia (ALL)
1 trial -
KPT-9274
Karyopharm Therapeutics Inc
Acute Myeloid Leukemia
1 trial -
KPT-9274
Karyopharm Therapeutics Inc
Solid Tumors
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Soft Tissue Sarcoma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Prolymphocytic Leukemia
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Solid Tumor
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Refractory Multiple Myeloma
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Amyloid
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Colorectal Neoplasm
1 trial -
Selinexor
Karyopharm Therapeutics Inc
Liposarcoma
1 trial -
Selinexor Pill
Karyopharm Therapeutics Inc
Hepatocellular Carcinoma
1 trial -
Venetoclax
Karyopharm Therapeutics Inc
Diffuse Large B-cell Lymphoma
1 trial -
Venetoclax
Karyopharm Therapeutics Inc
Acute Leukemia of Ambiguous Lineage in Relapse
1 trial -
Verdinexor
Karyopharm Therapeutics Inc
Healthy
1 trial -
decitabine
Karyopharm Therapeutics Inc
Acute Myeloid Leukemia
1 trial -
mitoxantrone hydrochloride
Karyopharm Therapeutics Inc
Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities
1 trial -
selinexor
Karyopharm Therapeutics Inc
Recurrent Melanoma
1 trial -
selinexor
Karyopharm Therapeutics Inc
B-cell Lymphoma
1 trial -
standard dose capecitabine
Karyopharm Therapeutics Inc
Rectal Neoplasms
1 trial
Frequently asked questions
How many clinical projects does Karyopharm Therapeutics have?
24 published programs are linked to this sponsor in our ClinicalTrials.gov index.
Is this the complete company pipeline?
This directory lists published programs for the sponsor in our database. Partnered or out-licensed assets may appear under multiple companies.